
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8504314/publications.pdf Version: 2024-02-01



SADAH LLODD

#	Article	lF	CITATIONS
1	Incorporating circulating tumor DNA detection to radiographic assessment for treatment response in advanced EGFR-mutant lung cancer. Lung Cancer, 2022, 163, 14-18.	0.9	2
2	The validity of progressionâ€free survival 2 as a surrogate trial end point for overall survival. Cancer, 2022, 128, 1449-1457.	2.0	15
3	Pre―and onâ€ŧreatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non–small cell lung cancer. Cancer, 2022, 128, 1574-1583.	2.0	14
4	De novo and recurrent metastatic breast cancer – A systematic review of population-level changes in survival since 1995. EClinicalMedicine, 2022, 44, 101282.	3.2	13
5	The Impact of Surveillance Imaging Frequency on the Detection of Distant Disease for Patients with Resected Stage III Melanoma. Annals of Surgical Oncology, 2022, 29, 2871-2881.	0.7	5
6	Simulations found within-subject measurement variation in glycaemic measures may cause overdiagnosis of prediabetes and diabetes. Journal of Clinical Epidemiology, 2022, 145, 20-28.	2.4	2
7	PD-L1 expression as a prognostic marker in patients treated with chemotherapy for metastatic non-small-cell lung cancer. Future Oncology, 2022, 18, 1793-1799.	1.1	6
8	Cost-Effectiveness of PET/CT Surveillance Schedules to Detect Distant Recurrence of Resected Stage III Melanoma. International Journal of Environmental Research and Public Health, 2022, 19, 2331.	1.2	1
9	Prevalence and characteristics of frequent presenters to Auburn Hospital emergency department. EMA - Emergency Medicine Australasia, 2022, , .	0.5	0
10	Adverse events in the placebo arm of maintenance therapy trials in advanced ovarian cancer: A systematic review and meta-analysis. European Journal of Cancer, 2022, 170, 169-178.	1.3	2
11	Setting minimum clinical performance specifications for tests based on disease prevalence and minimum acceptable positive and negative predictive values: Practical considerations applied to COVID-19 testing. Clinical Biochemistry, 2021, 88, 18-22.	0.8	5
12	How often are patients with clinically apparent inguinal hernias referred to a surgeon accompanied with an ultrasound? A prospective multicentre study. Australian Health Review, 2021, 45, 36.	0.5	3
13	Performance of Long-Term CT and PET/CT Surveillance for Detection of Distant Recurrence in Patients with Resected Stage IIIA–D Melanoma. Annals of Surgical Oncology, 2021, 28, 4561-4569.	0.7	11
14	Guidance for the design and reporting of studies evaluating the clinical performance of tests for present or past SARS-CoV-2 infection. BMJ, The, 2021, 372, n568.	3.0	18
15	Use of multiparametric magnetic resonance imaging (mpMRI) in active surveillance for low-risk prostate cancer: a scoping review on the benefits and harm of mpMRI in different biopsy scenarios. Prostate Cancer and Prostatic Diseases, 2021, 24, 662-673.	2.0	8
16	Impact of ultrasound on inguinal hernia repair rates in Australia: a populationâ€based analysis. ANZ Journal of Surgery, 2021, 91, 1604-1609.	0.3	1
17	Clinical utility of plasma EGFR mutation detection with quantitative PCR in advanced lung cancer: A meta-analysis. Lung Cancer, 2021, 154, 113-117.	0.9	5
18	Reporting the trajectories of adverse events over the entire treatment course in patients with recurrent platinum-sensitive ovarian cancer treated with platinum-based combination chemotherapy regimens: A graphical approach to trial adverse event reporting. European Journal of Cancer, 2021, 148, 251-259.	1.3	2

#	Article	IF	CITATIONS
19	Reply to: CT and PET/CT Surveillance in Stage IIIA-D Melanoma Results in More False-Positive Than True-Positive Findings and Should Not be Routinely Recommended, by Nicholas Taylor et al Annals of Surgical Oncology, 2021, 28, 819-820.	0.7	4
20	Tumor Response End Points as Surrogates for Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-Analysis. JCO Precision Oncology, 2021, 5, 1151-1159.	1.5	16
21	Trastuzumab emtansine for HER2-positive metastatic breast cancer: Outcomes from a whole-of-population Australian cohort. Breast, 2021, 58, 106-112.	0.9	6
22	1018Long-term risk of distant metastasis and post-metastasis survival for breast cancer: health record linkage study. International Journal of Epidemiology, 2021, 50, .	0.9	0
23	971Ethnicity and Cardiovascular Disease in the Australian Population. International Journal of Epidemiology, 2021, 50, .	0.9	0
24	Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy. European Journal of Cancer, 2021, 154, 190-200.	1.3	9
25	Setting analytical performance specifications using HbA1c as a model measurand. Clinica Chimica Acta, 2021, 523, 407-414.	0.5	6
26	Efficacy of immune checkpoint inhibitors in older adults with advanced stage cancers: A meta-analysis. Journal of Geriatric Oncology, 2020, 11, 508-514.	0.5	23
27	The impact of smoking on the effectiveness of immune checkpoint inhibitors — a systematic review and meta-analysis. Acta Oncológica, 2020, 59, 96-100.	0.8	13
28	Benchmarking single-arm studies against historical controls from non-small cell lung cancer trials – an empirical analysis of bias. Acta Oncológica, 2020, 59, 90-95.	0.8	6
29	The association between ethnicity and preâ€eclampsia in Australia: A multicentre retrospective cohort study. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2020, 60, 396-404.	0.4	9
30	The impact of neutrophil-lymphocyte ratio on risk reclassification of patients with advanced renal cell cancer to guide risk-directed therapy. Acta Oncológica, 2020, 59, 20-27.	0.8	3
31	Prediction of pre-eclampsia in nulliparous women using routinely collected maternal characteristics: a model development and validation study. BMC Pregnancy and Childbirth, 2020, 20, 23.	0.9	14
32	Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy. European Journal of Cancer, 2020, 139, 59-67.	1.3	12
33	Cost-effectiveness analysis of PET/CT surveillance imaging to detect systemic recurrence in resected stage III melanoma: study protocol. BMJ Open, 2020, 10, e037857.	0.8	4
34	Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials. JAMA Network Open, 2020, 3, e2011809.	2.8	33
35	Development and temporal validation of a prognostic model for 1-year clinical outcome after decompression surgery for lumbar disc herniation. European Spine Journal, 2020, 29, 1742-1751.	1.0	13
36	The AEDUCATE Collaboration. Comprehensive antenatal education birth preparation programmes to reduce the rates of caesarean section in nulliparous women. Protocol for an individual participant data prospective meta-analysis. BMJ Open, 2020, 10, e037175.	0.8	5

#	Article	IF	CITATIONS
37	Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer. Future Oncology, 2019, 15, 2371-2383.	1.1	4
38	Metastatic breast cancer incidence, site and survival in Australia, 2001–2016: a population-based health record linkage study protocol. BMJ Open, 2019, 9, e026414.	0.8	17
39	Setting clinical performance specifications to develop and evaluate biomarkers for clinical use. Annals of Clinical Biochemistry, 2019, 56, 527-535.	0.8	23
40	False-Positive Results and Incidental Findings with Annual CT or PET/CT Surveillance in Asymptomatic Patients with Resected Stage III Melanoma. Annals of Surgical Oncology, 2019, 26, 1860-1868.	0.7	29
41	Reply to Q. Wu et al Asia-Pacific Journal of Clinical Oncology, 2019, 15, 191-191.	0.7	1
42	Evaluation of Phase II Trial Design in Advanced Pancreatic Cancer. Pancreas, 2019, 48, 1274-1284.	0.5	2
43	The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis. Breast Cancer Research and Treatment, 2019, 174, 271-278.	1.1	31
44	Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers. JAMA Oncology, 2018, 4, 522.	3.4	92
45	Treatmentâ€related toxicities of immune checkpoint inhibitors in advanced cancers: A metaâ€analysis. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 141-152.	0.7	54
46	Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma. JAMA Oncology, 2018, 4, 210.	3.4	437
47	The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 792-800.	0.5	17
48	Circumferentially oversewn inverted stapled anastomosis. ANZ Journal of Surgery, 2018, 88, E232-E236.	0.3	4
49	Trastuzumab for metastatic breast cancer: Real world outcomes from an Australian whole-of-population cohort (2001–2016). Breast, 2018, 38, 7-13.	0.9	23
50	ICare-ACS (Improving Care Processes for Patients With Suspected Acute Coronary Syndrome). Circulation, 2018, 137, 354-363.	1.6	32
51	Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006–2014). British Journal of Cancer, 2018, 118, 441-447.	2.9	13
52	Assessment of NICE and USPSTF guidelines for identifying women at high risk of pre-eclampsia for tailoring aspirin prophylaxis in pregnancy: An individual participant data meta-analysis. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2018, 229, 159-166.	0.5	21
53	Performance of four published risk models to predict sentinel lymph-node involvement in Australian women with early breast cancer. Breast, 2018, 41, 82-88.	0.9	2
54	Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001–2016). Breast Cancer Research and Treatment, 2018, 171, 151-159.	1.1	20

#	Article	IF	CITATIONS
55	Adherence to prescribing restrictions for HER2-positive metastatic breast cancer in Australia: A national population-based observational study (2001-2016). PLoS ONE, 2018, 13, e0198152.	1.1	4
56	Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591878850.	1.4	4
57	Total Hip Arthroplasty by the Direct Anterior Approach Using a Neck-preserving Stem. Indian Journal of Orthopaedics, 2018, 52, 124-132.	0.5	11
58	Practical guide for identifying unmet clinical needs for biomarkers. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2018, 29, 129-137.	0.7	19
59	Changes in gene expression of neoâ€squamous mucosa after endoscopic treatment for dysplastic Barrett's esophagus and intramucosal adenocarcinoma. United European Gastroenterology Journal, 2017, 5, 13-20.	1.6	1
60	Driving After Microinvasive Total Hip Arthroplasty. Journal of Arthroplasty, 2017, 32, 1525-1529.	1.5	14
61	The prognostic value of TP53 mutations in oesophageal adenocarcinoma: a systematic review and meta-analysis. Gut, 2017, 66, 399-410.	6.1	31
62	Reversibility of nerve root sedimentation sign in lumbar spinal stenosis patients after decompression surgery. European Spine Journal, 2017, 26, 2573-2580.	1.0	11
63	Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: protocol detailing observations in a whole of population cohort. BMJ Open, 2017, 7, e014439.	0.8	15
64	Rapid Rule-out of Acute Myocardial Infarction With a Single High-Sensitivity Cardiac Troponin T Measurement Below the Limit of Detection. Annals of Internal Medicine, 2017, 166, 715.	2.0	231
65	Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival. Journal of the National Cancer Institute, 2017, 109, .	3.0	196
66	Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR -Mutated Non–Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 633-643.	0.5	122
67	How will transitioning from cytology to <scp>HPV</scp> testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in <scp>A</scp> ustralia, a high vaccination coverage country. International Journal of Cancer, 2017, 141, 2410-2422.	2.3	25
68	Clinical Equipoise for Trials of Novel Biologic Therapies, Therapeutic Success Rates, and Predictors of Success: A Meta-Analysis. JCO Precision Oncology, 2017, 1, 1-12.	1.5	1
69	Checkpoint Inhibitors in Metastatic EGFR- Mutated Non–Small Cell Lung Cancer—A Meta-Analysis. Journal of Thoracic Oncology, 2017, 12, 403-407.	0.5	653
70	Osseointegrated total hip replacement connected to a lower limb prosthesis: a proof-of-concept study with three cases. Journal of Orthopaedic Surgery and Research, 2016, 11, 13.	0.9	13
71	Effectiveness of EDACS Versus ADAPT Accelerated Diagnostic Pathways for Chest Pain: A Pragmatic Randomized Controlled Trial Embedded Within Practice. Annals of Emergency Medicine, 2016, 68, 93-102.e1.	0.3	107
72	CD151 Gene and Protein Expression Provides Independent Prognostic Information for Patients with Adenocarcinoma of the Esophagus and Gastroesophageal Junction Treated by Esophagectomy. Annals of Surgical Oncology, 2016, 23, 746-754.	0.7	7

. –

#	ARTICLE	IF	CITATIONS
73	Biomarker development targeting unmet clinical needs. Clinica Chimica Acta, 2016, 460, 211-219.	0.5	39
74	Letter to the Editor concerning "Relationship between sedimentation sign and morphological grade in symptomatic lumbar spinal stenosis―(by Laudato PA, Kulik G, Schizas C (2015) Eur Spine J;) Tj ETQqO 0 0 rgB1	Overlock	₹ 100Tf 50 697
75	The performance of risk prediction models for preâ€eclampsia using routinely collected maternal characteristics and comparison with models that include specialised tests and with clinical guideline decision rules: a systematic review. BJOG: an International Journal of Obstetrics and Gynaecology, 2016. 123. 1441-1452.	1.1	70
76	Safety of Osseointegrated Implants for Transfemoral Amputees. Journal of Bone and Joint Surgery - Series A, 2016, 98, 900-909.	1.4	120
77	Evaluation of High-Sensitivity Cardiac Troponin I Levels in Patients With Suspected Acute Coronary Syndrome. JAMA Cardiology, 2016, 1, 405.	3.0	75
78	Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer. Journal of Clinical Oncology, 2016, 34, 936-944.	0.8	17
79	Minimally invasive medial patellofemoral ligament reconstruction for patellar instability using an artificial ligament: A two year follow-up. Knee, 2016, 23, 261-266.	0.8	13
80	The Deckled Incision: Study Protocol for a Randomized Controlled Trial. JMIR Research Protocols, 2016, 5, e97.	0.5	0
81	The Relative Benefits and Costs of Solid Phase Bead Technology to Detect Preformed Donor Specific Antihuman Leukocyte Antigen Antibodies in Determining Suitability for Kidney Transplantation. Transplantation, 2015, 99, 957-964.	0.5	11
82	Australian clinical trial activity and burden of disease: an analysis of registered trials in National Health Priority Areas. Medical Journal of Australia, 2015, 203, 97-101.	0.8	8
83	Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: Analysis of the CALYPSO trial. Gynecologic Oncology, 2015, 136, 18-24.	0.6	39
84	Australian clinical practice guidelines for the diagnosis and management of <scp>B</scp> arrett's esophagus and early esophageal adenocarcinoma. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 804-820.	1.4	104
85	MIC-1/GDF15 in Barrett's oesophagus and oesophageal adenocarcinoma. British Journal of Cancer, 2015, 112, 1384-1391.	2.9	16
86	Setting analytical performance specifications based on outcome studies – is it possible?. Clinical Chemistry and Laboratory Medicine, 2015, 53, 841-8.	1.4	45
87	Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib. European Journal of Cancer, 2015, 51, 852-860.	1.3	23
88	Impact of Specific Epidermal Growth Factor Receptor ( <i>EGFR</i> ) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in <i>EGFR</i> -Mutant Lung Cancer: A Meta-Analysis. Journal of Clinical Oncology, 2015, 33, 1958-1965.	0.8	280
89	High Expression of Cathepsin E in Tissues but Not Blood of Patients with Barrett's Esophagus and Adenocarcinoma. Annals of Surgical Oncology, 2015, 22, 2431-2438.	0.7	13
90	Osseointegrated total knee replacement connected to a lower limb prosthesis: 4 cases. Monthly Notices of the Royal Astronomical Society: Letters, 2015, 86, 740-744.	1.2	30

#	Article	IF	CITATIONS
91	Metastatic breast cancer in young women: a populationâ€based cohort study to describe risk and prognosis. Internal Medicine Journal, 2014, 44, 764-770.	0.5	21
92	From biomarkers to medical tests: The changing landscape of test evaluation. Clinica Chimica Acta, 2014, 427, 49-57.	0.5	148
93	Esophageal Dysmotility After Laparoscopic Gastric Band Surgery. Obesity Surgery, 2014, 24, 625-630.	1.1	5
94	Increased intraoperative epidural pressure in lumbar spinal stenosis patients with a positive nerve root sedimentation sign. European Spine Journal, 2014, 23, 985-990.	1.0	25
95	A 2-Hour Diagnostic Protocol for Possible Cardiac Chest Pain in the Emergency Department. JAMA Internal Medicine, 2014, 174, 51.	2.6	151
96	A conceptual model of compensation/decompensation in lumbar segmental instability. Medical Hypotheses, 2014, 83, 312-316.	0.8	15
97	Clinical validity of the nerve root sedimentation sign in patients with suspected lumbar spinal stenosis. Spine Journal, 2014, 14, 667-674.	0.6	30
98	A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer. Annals of Oncology, 2013, 24, 937-943.	0.6	32
99	A KT intervention including the evidence alert system to improve clinician's evidence-based practice behavior—a cluster randomized controlled trial. Implementation Science, 2013, 8, 132.	2.5	32
100	Markers of systemic inflammation predict survival in patients with advanced renal cell cancer. British Journal of Cancer, 2013, 109, 147-153.	2.9	130
101	Letters. Spine, 2013, 38, 968.	1.0	2
102	Risk assessment to guide prostate cancer screening decisions: a costâ€effectiveness analysis. Medical Journal of Australia, 2013, 198, 546-550.	0.8	20
103	Effectiveness and cost-effectiveness of sentinel lymph node biopsy compared with axillary node dissection in patients with early-stage breast cancer: a decision model analysis. British Journal of Cancer, 2012, 106, 1045-1052.	2.9	33
104	Expenditure and resource utilisation for cervical screening in Australia. BMC Health Services Research, 2012, 12, 446.	0.9	18
105	Incidence of metastatic breast cancer in an Australian populationâ€based cohort of women with nonâ€metastatic breast cancer at diagnosis. Medical Journal of Australia, 2012, 196, 688-692.	0.8	34
106	Effect of dependent errors in the assessment of diagnostic or screening test accuracy when the reference standard is imperfect. Statistics in Medicine, 2012, 31, 1129-1138.	0.8	28
107	LINKING THE EVIDENCE: INTERMEDIATE OUTCOMES IN MEDICAL TEST ASSESSMENTS. International Journal of Technology Assessment in Health Care, 2012, 28, 52-58.	0.2	15
108	Using patient management as a surrogate for patient health outcomes in diagnostic test evaluation. BMC Medical Research Methodology, 2012, 12, 12.	1.4	31

#	Article	IF	CITATIONS
109	Clinical validation study to measure the performance of the Nerve Root Sedimentation Sign for the diagnosis of lumbar spinal stenosis. Contemporary Clinical Trials, 2011, 32, 470-474.	0.8	13
110	A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer. Breast Cancer Research and Treatment, 2011, 129, 467-476.	1.1	12
111	Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer. Journal of the National Cancer Institute, 2011, 103, 1338-1342.	3.0	33
112	Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer. British Journal of Cancer, 2011, 105, 1144-1150.	2.9	32
113	Carboplatin–paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer. British Journal of Cancer, 2011, 105, 360-365.	2.9	28
114	Nerve Root Sedimentation Sign. Spine, 2010, 35, 892-897.	1.0	87
115	Cervical cancer screening in Australia: modelled evaluation of the impact of changing the recommended interval from two to three years. BMC Public Health, 2010, 10, 734.	1.2	35
116	Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer. British Journal of Cancer, 2010, 102, 1341-1347.	2.9	39
117	A cost-effectiveness analysis of in-vitro fertilization by maternal age and number of treatment attempts. Human Reproduction, 2010, 25, 924-931.	0.4	36
118	Gene expression alterations in formalin-fixed, paraffin-embedded Barrett esophagus and esophageal adenocarcinoma tissues Cancer Biology and Therapy, 2010, 10, 172-179.	1.5	22
119	Molecular biomarkers to individualise treatment: assessing the evidence. Medical Journal of Australia, 2009, 190, 631-636.	0.8	23
120	ls perioperative point-of-care prothrombin time testing accurate compared to the standard laboratory test?. Thrombosis and Haemostasis, 2009, 102, 779-786.	1.8	18
121	Breast cancer screening: emerging role of new imaging techniques as adjuncts to mammography. Medical Journal of Australia, 2009, 190, 493-498.	0.8	29
122	Using the Principles of Randomized Controlled Trial Design to Guide Test Evaluation. Medical Decision Making, 2009, 29, E1-E12.	1.2	66
123	Magnetic Resonance Imaging Screening of the Contralateral Breast in Women With Newly Diagnosed Breast Cancer: Systematic Review and Meta-Analysis of Incremental Cancer Detection and Impact on Surgical Management. Journal of Clinical Oncology, 2009, 27, 5640-5649.	0.8	258
124	Accuracy and Surgical Impact of Magnetic Resonance Imaging in Breast Cancer Staging: Systematic Review and Meta-Analysis in Detection of Multifocal and Multicentric Cancer. Journal of Clinical Oncology, 2008, 26, 3248-3258.	0.8	705
125	Breast Cancer Risk and Hormone Receptor Status in Older Women by Parity, Age of First Birth, and Breastfeeding: A Case-Control Study. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1723-1730.	1.1	94
126	Systematic review of the impact of endoscopic ultrasound on the management of patients with esophageal cancer. International Journal of Technology Assessment in Health Care, 2008, 24, 25-35.	0.2	13

#	Article	IF	CITATIONS
127	Cost analysis of Gamma Knife stereotactic radiosurgery. International Journal of Technology Assessment in Health Care, 2007, 23, 488-494.	0.2	13
128	What Is the Value of Computered Tomography Colonography in Patients Screening Positive for Fecal Occult Blood? A Systematic Review and Economic Evaluation. Clinical Gastroenterology and Hepatology, 2007, 5, 1439-1446.	2.4	14
129	A Philosophical Approach to Diagnostic Test Evaluation. Annals of Internal Medicine, 2007, 146, 757.	2.0	0
130	Value of magnetic resonance cholangiopancreatography in the diagnosis of biliary abnormalities in postcholecystectomy patients: A probabilistic cost-effectiveness analysis of diagnostic strategies. International Journal of Technology Assessment in Health Care, 2006, 22, 109-118.	0.2	22
131	When Is Measuring Sensitivity and Specificity Sufficient To Evaluate a Diagnostic Test, and When Do We Need Randomized Trials?. Annals of Internal Medicine, 2006, 144, 850.	2.0	231
132	Review: computed tomographic colonography is accurate for medium and large colorectal polyps and cancer. Evidence-Based Medicine, 2006, 11, 153-153.	0.6	0
133	A systematic review and economic analysis of drugâ€eluting coronary stents available in Australia. Medical Journal of Australia, 2005, 183, 464-471.	0.8	28
134	Reproductive factors and subtypes of breast cancer defined by hormone receptor and histology. British Journal of Cancer, 2005, 93, 364-371.	2.9	117
135	Polymorphisms in genes involved in estrogen and progesterone metabolism and mammographic density changes in women randomized to postmenopausal hormone therapy: results from a pilot study. Breast Cancer Research, 2005, 7, R336-44.	2.2	30
136	Multiple analyses in clinical trials: sound science or data dredging?. Medical Journal of Australia, 2004, 181, 452-454.	0.8	22
137	Reproductive factors and risk of breast carcinoma in a study of white and African-American women. Cancer, 2004, 101, 353-362.	2.0	72